Vaccination with amyloid-β peptide induces autoimmune encephalomyelitis in C57/BL6 mice

Roberto Furlan, Elena Brambilla, Francesca Sanvito, Luca Roccatagliata, Stefano Olivieri, Alessandra Bergami, Stefano Pluchino, Antonio Uccelli, Giancarlo Comi, Gianvito Martino

Research output: Contribution to journalArticle

116 Citations (Scopus)

Abstract

Recent experimental evidence shows that vaccination with amyloid-β peptide (Aβ) of transgenic mouse models of Alzheimer's disease protects from the pathological accumulation of amyloid within the CNS. Phase I/lI clinical trials of Aβ vaccination in mild to moderate Alzheimer's disease have been undertaken. Unexpectedly, one of these trials has been suspended because 15 patients showed clinical signs consistent with CNS inflammation. Here, we show that C57BL/6 mice immunized with Aβ1-42 peptide develop an inflammatory disease of the CNS characterized by the presence both in the brain and spinal cord of perivenular inflammatory foci containing macrophages, T and B cells, and immunoglobulins. The experimental disease was observed only when pertussis toxin, an agent known to favour autoimmune processes, was co-administered. The immune-mediated CNS reaction was associated to Aβ-induced CD4+ cells showing a Th1-type cytokine expression profile and to elevated levels of circulating anti-Aβ immunoglobulins. Our results indicate that vaccination with Aβ could determine, under certain circumstances, an aberrant autoimmune-type reaction to Aβ resulting in a perivenular inflammatory encephalomyelitis.

Original languageEnglish
Pages (from-to)285-291
Number of pages7
JournalBrain
Volume126
Issue number2
DOIs
Publication statusPublished - Feb 1 2003

Fingerprint

Encephalomyelitis
Amyloid
Vaccination
Peptides
Immunoglobulins
Alzheimer Disease
Clinical Trials, Phase I
Central Nervous System Diseases
Pertussis Toxin
Inbred C57BL Mouse
Transgenic Mice
Spinal Cord
B-Lymphocytes
Macrophages
Cytokines
Inflammation
T-Lymphocytes
Brain

Keywords

  • Alzheimer's disease
  • Amyloid-β peptide
  • Encephalomyelitis
  • Vaccination

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Vaccination with amyloid-β peptide induces autoimmune encephalomyelitis in C57/BL6 mice. / Furlan, Roberto; Brambilla, Elena; Sanvito, Francesca; Roccatagliata, Luca; Olivieri, Stefano; Bergami, Alessandra; Pluchino, Stefano; Uccelli, Antonio; Comi, Giancarlo; Martino, Gianvito.

In: Brain, Vol. 126, No. 2, 01.02.2003, p. 285-291.

Research output: Contribution to journalArticle

Furlan, R, Brambilla, E, Sanvito, F, Roccatagliata, L, Olivieri, S, Bergami, A, Pluchino, S, Uccelli, A, Comi, G & Martino, G 2003, 'Vaccination with amyloid-β peptide induces autoimmune encephalomyelitis in C57/BL6 mice', Brain, vol. 126, no. 2, pp. 285-291. https://doi.org/10.1093/brain/awg031
Furlan, Roberto ; Brambilla, Elena ; Sanvito, Francesca ; Roccatagliata, Luca ; Olivieri, Stefano ; Bergami, Alessandra ; Pluchino, Stefano ; Uccelli, Antonio ; Comi, Giancarlo ; Martino, Gianvito. / Vaccination with amyloid-β peptide induces autoimmune encephalomyelitis in C57/BL6 mice. In: Brain. 2003 ; Vol. 126, No. 2. pp. 285-291.
@article{97b7d17480b4429cbf05ea7cfc3420f2,
title = "Vaccination with amyloid-β peptide induces autoimmune encephalomyelitis in C57/BL6 mice",
abstract = "Recent experimental evidence shows that vaccination with amyloid-β peptide (Aβ) of transgenic mouse models of Alzheimer's disease protects from the pathological accumulation of amyloid within the CNS. Phase I/lI clinical trials of Aβ vaccination in mild to moderate Alzheimer's disease have been undertaken. Unexpectedly, one of these trials has been suspended because 15 patients showed clinical signs consistent with CNS inflammation. Here, we show that C57BL/6 mice immunized with Aβ1-42 peptide develop an inflammatory disease of the CNS characterized by the presence both in the brain and spinal cord of perivenular inflammatory foci containing macrophages, T and B cells, and immunoglobulins. The experimental disease was observed only when pertussis toxin, an agent known to favour autoimmune processes, was co-administered. The immune-mediated CNS reaction was associated to Aβ-induced CD4+ cells showing a Th1-type cytokine expression profile and to elevated levels of circulating anti-Aβ immunoglobulins. Our results indicate that vaccination with Aβ could determine, under certain circumstances, an aberrant autoimmune-type reaction to Aβ resulting in a perivenular inflammatory encephalomyelitis.",
keywords = "Alzheimer's disease, Amyloid-β peptide, Encephalomyelitis, Vaccination",
author = "Roberto Furlan and Elena Brambilla and Francesca Sanvito and Luca Roccatagliata and Stefano Olivieri and Alessandra Bergami and Stefano Pluchino and Antonio Uccelli and Giancarlo Comi and Gianvito Martino",
year = "2003",
month = "2",
day = "1",
doi = "10.1093/brain/awg031",
language = "English",
volume = "126",
pages = "285--291",
journal = "Brain",
issn = "0006-8950",
publisher = "Oxford University Press",
number = "2",

}

TY - JOUR

T1 - Vaccination with amyloid-β peptide induces autoimmune encephalomyelitis in C57/BL6 mice

AU - Furlan, Roberto

AU - Brambilla, Elena

AU - Sanvito, Francesca

AU - Roccatagliata, Luca

AU - Olivieri, Stefano

AU - Bergami, Alessandra

AU - Pluchino, Stefano

AU - Uccelli, Antonio

AU - Comi, Giancarlo

AU - Martino, Gianvito

PY - 2003/2/1

Y1 - 2003/2/1

N2 - Recent experimental evidence shows that vaccination with amyloid-β peptide (Aβ) of transgenic mouse models of Alzheimer's disease protects from the pathological accumulation of amyloid within the CNS. Phase I/lI clinical trials of Aβ vaccination in mild to moderate Alzheimer's disease have been undertaken. Unexpectedly, one of these trials has been suspended because 15 patients showed clinical signs consistent with CNS inflammation. Here, we show that C57BL/6 mice immunized with Aβ1-42 peptide develop an inflammatory disease of the CNS characterized by the presence both in the brain and spinal cord of perivenular inflammatory foci containing macrophages, T and B cells, and immunoglobulins. The experimental disease was observed only when pertussis toxin, an agent known to favour autoimmune processes, was co-administered. The immune-mediated CNS reaction was associated to Aβ-induced CD4+ cells showing a Th1-type cytokine expression profile and to elevated levels of circulating anti-Aβ immunoglobulins. Our results indicate that vaccination with Aβ could determine, under certain circumstances, an aberrant autoimmune-type reaction to Aβ resulting in a perivenular inflammatory encephalomyelitis.

AB - Recent experimental evidence shows that vaccination with amyloid-β peptide (Aβ) of transgenic mouse models of Alzheimer's disease protects from the pathological accumulation of amyloid within the CNS. Phase I/lI clinical trials of Aβ vaccination in mild to moderate Alzheimer's disease have been undertaken. Unexpectedly, one of these trials has been suspended because 15 patients showed clinical signs consistent with CNS inflammation. Here, we show that C57BL/6 mice immunized with Aβ1-42 peptide develop an inflammatory disease of the CNS characterized by the presence both in the brain and spinal cord of perivenular inflammatory foci containing macrophages, T and B cells, and immunoglobulins. The experimental disease was observed only when pertussis toxin, an agent known to favour autoimmune processes, was co-administered. The immune-mediated CNS reaction was associated to Aβ-induced CD4+ cells showing a Th1-type cytokine expression profile and to elevated levels of circulating anti-Aβ immunoglobulins. Our results indicate that vaccination with Aβ could determine, under certain circumstances, an aberrant autoimmune-type reaction to Aβ resulting in a perivenular inflammatory encephalomyelitis.

KW - Alzheimer's disease

KW - Amyloid-β peptide

KW - Encephalomyelitis

KW - Vaccination

UR - http://www.scopus.com/inward/record.url?scp=0037317234&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037317234&partnerID=8YFLogxK

U2 - 10.1093/brain/awg031

DO - 10.1093/brain/awg031

M3 - Article

C2 - 12538398

AN - SCOPUS:0037317234

VL - 126

SP - 285

EP - 291

JO - Brain

JF - Brain

SN - 0006-8950

IS - 2

ER -